ArticleNoro psikiyatri arsivi2025
Comparison of Naltrexone Implant and Oral Buprenorphine Naloxone in The Treatment of Opioid Use Disorder: A Retrospective Cohort Study.
Article in Noro psikiyatri arsivi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The aim of this study is to compare the duration of abstinence and relapse risk of patients using oral buprenorphine-naloxone (BN-NX) and naltrexone implants (XR-NTX) in the maintenance treatment of opioid use disorder (OUD), and to examine the relationship between relapse risk and some sociodemographic and clinical features. Methods: Medical records, sociodemographic and clinical characteristics of 284 patients treated for OUD between 2021 and 2023 were retrospectively evaluated in terms of relapse risk and abstinence duration with BUP-NX (107 patients) or XR-NTX (177 patients) as maintenance therapy. Results: Post-treatment abstinence duration was significantly lower in the BN-NX group than in the XR-NTX group. (p=0.01). There was a statistically significant difference between the groups (BN-NX: 5.6 months, XR-NTX: 6.6 months) in terms of relapse times within 1 year (p=0.026). According to Cox regression analysis, it was concluded that the increase in the age of onset of drug use, the increase in the longest period of abstinence and the use of XR-NTX treatment reduced the risk of relapse, while the increase in the number of inpatient treatments, probation and multiple substance use increased the risk of relapse. Conclusion: The findings of our study show that XR-NTX may be more effective than BN-NX in preventing relapse in OUD. In addition, it was concluded that probation, age of onset of substance use, multiple substance use, number of inpatient treatments and longest period of abstinence were predictive factors in terms of relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.